STING and Nonnecroptotic MLKL‐Mediated Mechanisms Improve Dendritic Cell Maturation and Killing of Cancer Cells
Activation of the cGAS-STING pathway plays an important role in antitumor immunity through maturation of tumor-infiltrating DCs. DCs engulf extracellular DNA released by dying cancer cells, supporting activation of the cGAS-STING pathway and concomitant DC maturation. Extracellular DNA in the tumor microenvironment is primarily derived from cells undergoing uncontrolled necrosis or programmed inflammatory death, such as necroptosis, which can be induced when apoptosis pathways are inhibited. Here, we report that caspase inhibition primes activation of a RIPK1/3, MLKL, and STING signaling axis in DCs, resulting in maturation without the need for any further maturation stimuli such as LPS or TNF-α. Notably, these signaling events do not induce DC death, indicating a nonnecroptotic role of the RIPK1-RIPK3-MLKL pathway and novel crosstalk with the STING pathway. Caspase inhibition in DC/cancer cell co-cultures results in DC maturation, inducing TNF-α secretion, which delivers the co-signal to induce cancer cell necroptosis. In summary, we find a collaborative mechanism of the STING and necroptosis pathway in DC maturation, and that activation of the necroptosis pathway has opposite effects on cancer cells and DCs, proposing a possibility for new targets in cancer immunotherapy.
Authors
- Marlene Fyrstenberg Laursen (ORCID: https://orcid.org/0000-0002-2804-0026)
- Trine S. Jensen
- Emil Kofod‐Olsen (ORCID: https://orcid.org/0000-0003-2918-8978)
- Martin R. Jakobsen (ORCID: https://orcid.org/0000-0001-8847-9201)
- Ralf Agger (ORCID: https://orcid.org/0000-0002-1434-5726)
- Agnieszka Banasik
- Lea Schort
Institutions
- Aarhus University (DK)
- Aalborg University (DK)
Publication Details
- Journal
- European Journal of Immunology
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1002/eji.70044
- Citations
- 2
- Primary Topic
- interferon and immune responses
- Type
- article
- Field-Weighted Citation Impact
- 1.59
Funders
- Novo Nordisk Fonden
- Fabrikant Einar Willumsens Mindelegat